MDM shares its findings in journals and at professional conferences.



Publications

MDM has published in a variety of scientific journals. MDM’s publications are primarily model-focused and address a wide range of medical conditions. Furthermore, MDM personnel are frequent reviewers of manuscripts for the journals Medical Decision Making and Value in Health.

  • Kessler W, Imperiale T, Klein R, Wielage R, Rex D. A quantitative assessment of foregoing histologic examination of diminutive polyps. Endoscopy. 2011; (in press).

  • Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Montgomery W, Conley RR. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Current Med Res & Opin. 2011; 27(4): 713-30.

  • Yaesoubi R, Roberts SD, Klein RW. A modification of Cheng's method: an alternative factor screening method for stochastic simulation models. 2010 Winter Simulation Conference Proceedings, IEEE, Piscataway, NJ. 2010: 1034-47.

  • Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, Hsia J. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010 Sep;13(3):428-37.

  • Klein R, Wielage R, Muehlenbein C, Liepa AM, Babineaux S, Lawson A, Schwartzberg L. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010 Aug;5(8):1263-72.

  • Furiak NM, Klein RW, Kahle-Wrobleski K, Siemers ER, Sarpong E, Klein TM. Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model. BMC Med Inform Decis Mak. 2010 Apr 30;10:24.

  • Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R, Schwartzberg L. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2009 Nov;4(11):1404-14.

  • Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value in Health. 2010;13:77-86. First published online 24 Aug 2009.

  • Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Conley RR, Culler SD. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009 Apr 7;7:4.

  • Hass DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM. Tocolytic therapy: a meta-analysis and decision analysis. Obstetrics & Gynecology. 2009;113(3):585-94.

  • Tafazzoli A, Roberts S, Ness R, Klein R, Dittus R. Probabilistic cost-effectiveness comparison of screening strategies for colorectal cancer. ACM Transactions on Modeling and Computer Simulation. 2009;19(2):1-29.

  • Ascher-Svanum H, Zhu B, Faries DE, Furiak NM, Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes. 2009 Jan 12;2:6.

  • Roberts S, Wang L, Klein R, Ness R, Dittus R. Development of a simulation model of colorectal cancer. ACM Transactions on Modeling and Computer Simulation. 2008;18(1):1-30.

  • Smolen HJ, Cohen DJ, Samsa GP, Toole JF, Klein RW, Furiak NM, Lorell BH. Development, validation, and application of a microsimulation model to predict stroke and mortality in medically-managed asymptomatic patients with significant carotid artery stenosis. Value Health. 2007;10(6):489-97.

  • Imperiale TF, Klein RW, Chalasani N. A Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. Hepatology. 2007;45(4):870-8.

  • Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Women's Health. 2007;7:6. http://www.biomedcentral.com/content/pdf/1472-6874-7-6.pdf

  • Ness RM, Klein RW, Dittus RS. Appendix G The Vanderbilt Colorectal Cancer Model. In Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Pignone M, Russell L, Wagner J, eds. Washington DC, National Academies Press 2005. Available at:
    http://www.iom.edu/CMS/3798/15652/25197.aspx.

  • Ohsfeldt RL, Kreder KJ, Klein RW, Chrischilles EA. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. J Manag Care Pharm. 2004;10(5):412-22.

  • Imperiale TF, Chalasani N, Klein RW. Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis. Am J Gastroenterol. 2003;98(12):2742-50.

  • Ness RM, Holmes A, Klein R, Dittus R. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol. 2000;95(7):1800-11.

  • Ness RM, Holmes A, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999,94(7):1650-7.